Article
Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels.
EBioMedicine - 1 Jan 2021
Mohan Haneesha, Lenis Monica Guzman, Laurette Evelyn Y, Tejada Oscar, Sanghvi Tanvi, Leung Kit-Yi, Cahill Lindsay S, Sled John G, Delgado-Olguín Paul, Greene Nicholas D E, Copp Andrew J, Serghides Lena
Abstract excerpt
BACKGROUND: Dolutegravir (DTG) is a preferred regimen for all people with HIV including pregnant women, but its effects on the fetus are not fully understood. Periconceptional exposure to DTG has been associated with increased rates of neural tube defects (NTDs), although it is unknown whether this is a causal relationship. This has led to uncertainty around the use of DTG in women of reproductive potential....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.